Theravance THRX
-
More on Royalty Pharma/ Elan ([[ELN]] +3.3%): Royalty says ELN "dramatically overpaid" for its 21% participation interest in future royalty payments from Theravance's ([[ THRX ]] -5.9%) respiratory ...
… 21% participation interest in future royalty payments from Theravance 's ( THRX -5.9% ) respiratory collaborations with GlaxoSmithKline ..... share) is contingent upon shareholders voting against the THRX deal. Post your comment!
-
Elan Transformation Continues, but We Remain Skeptical of Deal Values
… proposed new business deals, and we're maintaining our fair value estimate as we digest the news in relation to last week's Theravance deal announcement. We're intrigued by Elan's decision to take a page out of Valeant's playbook, focusing on underpenetrated …
-
The Billion Dollar COPD Deal: Who Gains The Most?
… Corporation PLC ( ELN ) announced a $1 billion deal with Theravance Inc . ( THRX ) for 21% of royalty that it gets from GlaxoSmithKline ..... participation interest in future royalties that Theravance will receive from GlaxoSmithKline from sale of four …
-
The Benefits of Diversifying the Funding of a Gold Position
Theravance THRX reported second-quarter earnings that matched our expectations, and we are keeping our fair value estimate at $29 per share …
-
Theravance's CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Theravance , Inc. ( THRX ) Bank of America Merrill Lynch Health ..... a pleasure for me to introduce the Theravance team. We had Mike Aguiar, CFO up here ..... there, 15 years, and he has been at Theravance for a dozen years, and he is here to …
-
Theravance's CEO discusses 1 Billion Dollar Royalty Participation Agreement with Elan (Transcript)
Theravance , Inc. ( THRX ) Royalty Participation Agreement Call May 13, 2013 ..... d like to welcome everyone to the Theravance Conference Call. During the presentation ..... seekingalpha.com/article/1430061- theravance -and-elan-enter-into-a …
-
US STOCKS-Wall St dips but rise in retail sales limits decline
* Elan to buy part of U.S. drug firm Theravance 's royalty for $1 billion
-
Wall Street Breakfast: Must-Know News
Wall Street Breakfast Editors submit: Top Stories In China, economy sends mixed signals. Chinese industrial output growth printed at 9.3% in April, up from a seven-month low of 8.9% in March but still a whisker below economists' expectations of 9.4%. Investors were watching the data closely for ...
-
Elan's Theravance Deal Creates Passive Stake in Respiratory Disease; We Await Additional Deals
… Elan ELN has announced that it intends to pay $1 billion to Theravance for a 21% stake in its royalty stream from partner GlaxoSmithKline ..... The deal relates to four of the six programs included in Theravance 's 2002 LABA partnership with Glaxo: Relvar Ellipta/Breo …
-
Elan (ELN) will make a one time cash payment of $1B to Theravance ( THRX ) for a 21% participation interest in future royalty payments from THRX's four respiratory collaborations with GlaxoSmithKline ...
… one time cash payment of $1B to Theravance ( THRX ) for a 21% participation interest in future royalty payments from THRX 's four respiratory collaborations ..... The news comes on the heels of THRX 's earnings report and concurrent …